The effect of arabinoxylooligosaccharides on gastric sensory‐motor function and nutrient tolerance in man. Issue 8 (20th May 2016)

• Record Type: Journal Article
• Authors: Scarpellini, E.; Deloose, E.; Vos, R.; Francois, I. E. J. A.; Delcour, J. A.; Broekaert, W. F.; Verbeke, K.; Tack, J.
• Is Part Of: Neurogastroenterology & motility. Volume 28:Issue 8(2016)
• Page Start: 1194
• Page End: 1203
• Publication Date: 2016-05-20
• Subjects: AXOS -- barostat -- drink‐test; Gastrointestinal system -- Motility -- Periodicals; Gastrointestinal system -- Innervation -- Periodicals; 616.33
• DOI: 10.1111/nmo.12819
• Languages: English
• ISSNs: 1350-1925

Abstract

Abstract: Background: Intestinal microbiota regulates gastrointestinal sensory‐motor function. Prebiotics such as arabinoxylan‐oligosaccharide (AXOS) are non‐digestible, fermentable food ingredients beneficially affecting intestinal microbiota, colon activity, and improving human health. We wanted to investigate whether acute AXOS or maltodextrin (placebo) administration may alter gastric sensitivity (GS), accommodation (GA), nutrient tolerance (NT) in man. Methods: Thirteen HV (6 M, 32.2 ± 1.8 years; BMI 22.3 ± 0.2) underwent two 48 h treatment periods with oral 4 × 9.4 g AXOS or 4 × 10 g maltodextrin (at least 1 week wash‐out) for gastric barostat assessment of GS, gastric compliance (GC), GA to a liquid test meal, on day 1, and NT drink test, on day 2. Oro‐cecal transit‐time (OCTT), colonic fermentation (CF) were assessed simultaneously with 13 C‐lactose ureide, H2 breath tests. Key Results: Arabinoxylan‐oligosaccharide significantly increased CF on day 1 and 2 (565 ± 272 vs 100 ± 24, 365 ± 66 vs 281 ± 25 H2 ppm/min, AXOS vs maltodextrin, both p < 0.05), not the OCTT. AXOS did not alter GC, sensitivity before and after the meal. Gastric accommodation was not significantly influenced by AXOS (volume increment: 171 ± 33 vs 130 ± 28 mL, AXOS vs maltodextrin, p = NS). On day 1, AXOS fermentation was associated with significantly higher postprandial bloating scores (960 ± 235 vs 396 ± 138 mm*min, AXOS vs maltodextrin, p < 0.05). On day 2, AXOS did not affect maximal NT (946 ± 102 vs 894 ± 97 mL, AXOS vs maltodextrin, p = NS), increased the bloating score (1236 ± 339 vs 675 ± 197 mm*min, AXOS vs maltodextrin, p < 0.05). Conclusions & Inferences: Acute AXOS administration, associated with increased CF, does not affect GA, is not associated with increased meal‐induced satiety or perception scores. Abstract : Acute AXOS administration is associated with a significant colonic fermentation vs maltodextrin non fermentation. AXOS does not affect gastric sensorimotor function and nutrient tolerance in man, but its fermentation seems to be associated to higher bloating ratings in man.